Companies Dominating the Atenolol Landscape
- Intas Pharmaceuticals Limited
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd
- Danaher Corporation
- Bio-Rad Laboratories, Inc.
- Sysmex Corporation
- Zydus Pharmaceuticals (USA) Inc.
- Ipca Laboratories Limited
- Unichem Laboratories Limited
- AstraZeneca PLC
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of atenolol is assessed at USD 13.33 billion.
The atenolol market size was over USD 12.23 billion in 2024 and is anticipated to cross USD 24.53 billion by 2037, witnessing more than 5.5% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of angina experiences, expansion in sedentary lifestyle, and increasing prevalence of arrhythmia will boost the market growth.
North America industry is set to hold largest revenue share of 40% by 2037, attributed to increasing prevalence of cardiac diseases, along with rising frequency of hypertension in the region.
The major players in the market are Intas Pharmaceuticals Limited, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Danaher Corporation, Bio-Rad Laboratories, Inc., Sysmex Corporation, Zydus Pharmaceuticals (USA) Inc., Ipca Laboratories Limited, Unichem Laboratories Limited, AstraZeneca PLC
